Study: International, multicenter, phase 3 trial (ARASENS) Metastatic, hormone-sensitive prostate cancer Darolutamide (n=651) or placebo (n=654) with androgen-deprivation therapy and docetaxel. Efficacy: Median treatment duration: 41 m vs 16.7 months
Study: Randomized, double-blind, placebo-controlled trial (KEYNOTE-522) Previously untreated stage II or III triple-negative breast cancer Neoadjuvant/adjuvant pembrolizumab (n=784) or placebo (n=390) plus standard therapy Efficacy: 36-mo-EFS: 84.5% [81.7%-86.9%] vs 76.8%
Study: Global, randomized, open-label, phase 3 trial (CheckMate 648) Unresectable advanced, recurrent, or metastatic esophageal squamous-cell carcinoma with no previous systemic therapy for advanced disease Nivolumab plus chemotherapy (n=321) or
Study: Multicenter, international, phase 2 study Metastatic HER2-mutant NSCLC, refractory to standard treatment Trastuzumab deruxtecan (N=91) Efficacy: mPFS: 8.2 mos, mOS:17.8 mos mDOR: 9.3 mos Safety: All patients had adverse
Study: Double-blind, randomized Phase II-III trial Untreated metastatic or unresectable melanoma Relatlimab and nivolumab vs nivolumab alone Efficacy: mPFS: 10.1 vs 4.6 mos (HR:0.75; P=0.006) 12 months PFS: 47.7% vs
Study: Randomized phase III trial (MONALEESA-2) Postmenopausal, HR-positive, HER2-negative recurrent or metastatic breast cancer with no previous systemic therapy for advanced disease Ribociclib or placebo in combination with letrozole Efficacy:
Study: International, randomized, open label, noninferiority phase III Chemotherapy-naïve uterine or ovarian carcinosarcoma CARBOplatin + PACLitaxel (n=228) or Ifosfamide + PACLitaxel (n=221) for 6-10 cycles Efficacy: For UCS: mOS: 37
Study: Multicenter, nonrandomized phase II study HER2-mutated, advanced NSCLC with ≥ one previous line including platinums Pertuzumab+trastuzumab+docetaxel (n=45) Efficacy: ORR: 29%, SD: 58% mPFS: 6.8 mos, mOS: 17.6 mos 5
Study: Randomized phase II trial (GETUG-AFU V05 VESPER) Nonmetastatic muscle-invasive bladder cancer Dd-MVAC vs gemsitabin+cisplatin. Neoadjuvant OR adjuvant chemotherapy Efficacy: Organ confined response: 77% v 63% (p = 0.001) Neoadjuvant
Study: Multicenter, randomized controlled trial (PREOPANC) Resectable or borderline resectable pancreatic cancer 3 cycles of gemcitabine combined with RT (n=119) or upfront surgery plus adjuvant 4 cycles gemcitabine (n=127) Efficacy:
Study: Multicenter, international, phase 2 study Metastatic HER2-mutant NSCLC (refractory to standard treatment) Trastuzumab deruxtecan >= 6.4 mg per kilogram of body weight Efficacy: ORR: 55% (95% CI, 44 to
Study: Double-blind Phase III trial Untreated intermediate-risk or high-risk DLBCL Polatuzumab-R-CHP vs R-CHOP Efficacy: 2 years PFS: 76.7% vs 70.2% (HR:0.73 95% Cl 0.57-0.95 p=0.02) 2 years OS: 88.7% vs
Study: Open-label randomized trial (AIO KRK 0212) RAS Wild-type metastatic colorectal cancer Post first-line induction therapy with six cycles of FU/FA and oxaliplatin plus Pmab FU/FA plus Pmab or FU/FA
Study: Open-label Phase III trial Untreated HLA-A*02:01-positive patients with metastatic uveal melanoma Tebentafusp or the investigator’s choice of therapy with single-agent pembrolizumab, ipilimumab, or dacarbazine Efficacy: Median OS: 21.7 vs.
Study: Single arm cohort study Relapsed or refractory multiple myeloma Prior 1 to 3 lines therapy Daratumumab 1800 mg SC, hyaluronidase 30000 units SC, carfilzomib IV and dexamethasone peroral Efficacy:
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.